# Soquelitinib

Source: https://onco.cc/drugs/soquelitinib/  
OnCo record `soquelitinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Soquelitinib is an experimental small-molecule drug from Corvus Pharmaceuticals in phase 3 trials for peripheral T-cell lymphomas, with its target not yet stated publicly.

## Summary

Soquelitinib (CPI-818) is a small-molecule drug developed by Corvus Pharmaceuticals. The sponsor describes its target as ITK (interleukin-2-inducible T-cell kinase), which OnCo does not yet have a target page for. The sponsor states: An oral, selective ITK inhibitor that promotes Th1 helper cell development while suppressing Th2 and Th17 cells, and can shift differentiation toward regulatory T cells. ClinicalTrials.gov describes the intervention as: Soquelitinib 200 mg tablets will be taken by mouth two times a day. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06561048 (Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma), in peripheral T-cell lymphomas. The largest, NCT06561048, plans to enrol 150 participants with primary completion expected 2027-11. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: CPI-818
- Modality: small molecule
- Mechanism: An oral, selective ITK inhibitor that promotes Th1 helper cell development while suppressing Th2 and Th17 cells, and can shift differentiation toward regulatory T cells.

## Sources

- ClinicalTrials.gov: trials of Soquelitinib: https://clinicaltrials.gov/search?intr=CPI-818
- Sponsor pipeline page: https://corvuspharma.com/pipeline/

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- companies: [Corvus Pharmaceuticals](https://onco.cc/companies/corvus-pharmaceuticals/)
- trials: [Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma](https://onco.cc/trials/nct06561048/)
- targets: [ITK](https://onco.cc/targets/itk/)

---
JSON: https://onco.cc/api/v1/entities/soquelitinib.json